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Introduction: Among the sleep disorders reported by the American Academy of Sleep, the most common is obstructive 
sleep apnea-hypopnea syndrome (OSAHS), which is caused by difficulties in air passage and complete interruption of air 
flow in the airway. This syndrome is associated with increased morbidity and mortality in apneic individuals. 
Objective: It was the objective of this paper to evaluate a removable mandibular advancement device as it provides 
a noninvasive, straightforward treatment readily accepted by patients. 
Methods: In this study, 15 patients without temporomandibular disorders (TMD) and with excessive daytime 
sleepiness or snoring were evaluated. Data were collected by means of: Polysomnography before and after place-
ment of an intraoral appliance, analysis of TMD signs and symptoms using a patient history questionnaire, muscle 
and TMJ palpation. 
Results: After treatment, the statistical analysis (t-test, and the “before and after” test) showed a mean reduction of 
77.6% (p=0.001) in the apnea-hypopnea index, an increase in lowest oxyhemoglobin saturation (p=0.05), decrease in 
desaturation (p=0.05), decrease in micro-awakenings or EEG arousals (p=0.05) and highly significant improvement 
in daytime sleepiness (p=0.005), measured by the Epworth Sleepiness Scale. No TMD appeared during the monitor-
ing period. 
Conclusion: The oral device developed in this study was considered effective for mild to moderate OSAHS.
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IntROduCtIOn
One often hears that when a person is asleep and 
snoring, it means that they are fast and sound asleep. 
It couldn’t be farther from the truth. A partial obstruc-
tion in the upper airway causes snoring while a com-
plete obstruction leads to sleep apnea, which is the 
total cessation of airflow. These events comprise what 
is known as Sleep Apnea and Hypopnea Syndrome 
(OSHAS) and lead to serious consequences such as 
systemic and pulmonary hypertension, excessive 
daytime sleepiness, impaired memory, irritability, de-
pression, decreased libido, impotence, burnout, head-
ache and a proneness to workplace and car accidents. 
Apnea is characterized by an interruption in airflow 
(breathing) for at least ten seconds. Hypopnea is a 
50% reduction in airflow accompanied by a “micro-
awakening” or EEG arousal and/or a drop in blood 
oxyhemoglobin saturation (SaO2) of about 2% to 4%.4
It is diagnosed by examining sleep with polysom-
nography (PSG), which consists of simultaneously 
recording activities occurring in the organism during 
a given period and tracking not only the number of ap-
neas and hypopneas during the patient’s sleep but also 
defining OSHAS severity using the apnea-hypopnea 
index (AHI), which is the sum of apnea and hypopnea 
events per hour of sleep.6 
Several authors have confirmed the validity and 
effectiveness of oral appliances for OSHAS treat-
ment.1,2,5,8,9,10,16 Appliances that reposition the man-
dible anteriorly are indicated for primary snoring and 
mild to moderate OSAHS with an AHI of up to 30 4,9.  
In OSAHS patients this therapy can be effective 
even in the presence of other diseases such as conges-
tive heart failure and arterial hypertension,8,19,30 there-
by contributing to clinical control.
In treating OSHAS a correct diagnosis is of para-
mount importance, as well as a multidisciplinary 
team with training and knowledge of sleep disorders, 
and a reliable treatment indication for each case. 
Dentists should be part of this team as they play a key 
role both in the initial diagnosis, by referring the pa-
tient to polysomnography, and in the treatment itself 
after the examination. 
The purpose of this study was to develop an alter-
native intraoral appliance model for treating OSHAS, 
evaluate its effectiveness and magnitude of changes 
in AHI, and observe the side effects and development 
of potential TMD (temporomandibular dysfunction) 
signs and symptoms in the follow-up phase.
  
MateRIal and MetHOdS
The study evaluated 15 patients among those 
who presented voluntarily at the Clinic of Sleep 
Disorders located in Bauru, Brazil, reporting exces-
sive daytime sleepiness and/or snoring. Patients 
had a mean age of 49.9 years.
Initially, patients answered a questionnaire, the 
Epworth Sleepiness Scale (ESS), designed to mea-
sure their daytime sleepiness in specific situations,15 
including patients with ESS scores greater than five. 
Examination to check for the presence of Temporo-
mandibular Disorders (TMD) began with the pa-
tient’s clinical history using the Anamnesis Index 
(AI) questionnaire.7,11,18 The results were compared 
with the AI table, which classifies patients’ TMD, 
thus: 0-15, no TMD, 20-40, mild TMD, 45-65, moder-
ate TMD, 70-100, severe TMD. Thereafter, a physi-
cal and clinical examination was performed by digi-
tal palpation of the right and left TMJs and muscles 
(superficial and deep masseter, medial pterygoid and 
temporal). Patient response to TMJ palpation was 
graded as suggested by Pertes and Gross21 and as per-
formed by Miranda.18 Therefore, assessment of the 
development of TMD signs and symptoms was per-
formed by comparing AI before and after treatment, 
and also by physical examination, i.e., palpation of 
masticatory muscles and TMJ. 
Exclusion criteria were as follows: AI higher 
than 15 (since subjects with AI between zero and 
15 are considered without TMD, and above 15, with 
TMD) or presence of TMD signs and symptoms, 
moderate or severe periodontal disease, lower than 
6 mm maximum mandibular protrusion and less 
than 35 mm mouth opening. 
All patients underwent polysomnography (PSG) 
in the Clinic of Sleep Disorders before and after wear-
ing the appliance. The average time interval between 
PSGs was five months.
During fabrication, the adjustable mandibular 
advancement splints were waxed, made with an 
opening from canine to canine (1.5 mm on average) 
and processed. Stainless steel wires were also used 
for mechanical support to prevent the acrylic from 
fracturing. A 13 mm palate expander screw was 
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employed to join the maxillary to the mandibular 
portion of the splint (Fig 1). 
At each visit after splint insertion it was advanced 
by 0.25 mm until the mandibular advancements 
reached 1 mm within a two-week period. Patients were 
monitored on a weekly basis and, after reporting an 
improvement in snoring and sleepiness, were referred 
for a second PSG. After approximately six months 
wearing the splint, the patients were examined again 
to assess TMD development. 
The tests used for statistical analysis of the re-
sults included Student’s t-distribution test for small 
samples, with degree of freedom (df ) lower than 120 
and the “before and after” test which, in simple com-
parative experiments with samples that have the same 
origin, ensures greater accuracy than t-test. Both tests 
were applied to ensure outcome reliability.
ReSultS
Anthropometric data of the subjects who partici-
pated in the research are presented in Table 1.
The data were statistically evaluated by Student’s 
t-test and confirmed by the “before and after” test. 
Assessment results of daytime sleepiness before and 
after splint use are depicted in Table 2.
All patients exhibited decreased ESS values, not-
ing that the treatment reduced excessive daytime 
sleepiness in a highly significant manner in 87% of 
the patients (p=0.005).
It is noteworthy that AI variation was not sufficient 
to affect the TMD classification of any patient, i.e., it 
did not increase over 15. On physical examination by 
muscle palpation 14 patients showed no significant 
differences after treatment compared to muscle pal-
pation values found prior to treatment. 
During mandibular advancement therapy patients 
6 and 15 (13.3%) developed morning muscle pain.10 
Treatment included the prescription of oral medica-
tion (Celecoxib 200 mg) once a day for three days. The 
mandibular advancement was halted for a week and 
then restarted at 0.25 mm per week.2 The two patients 
were left with the splint positioned 1 mm below the 
75% of maximum protrusion mark. These two patients 
never again exhibited TMD signs and symptoms.
Table 4 presents the oxyhemoglobin saturation 
index, number of arousals and number of apneas 
and hypopneas occurring per hour during the first 
and second PSG.
On the one-tailed Student’s table for p=0.05 and 
df=14, tc = 1.761 with 95% confidence for the situation 
“with splint”, the amount of oxyhemoglobin desatura-
tion events decreased significantly.
For the one-tailed test tc=1.761 (hence to>tc), 
the number of arousals “after” is significantly low-
er than “before.”
Snoring, as evaluated by PSG, improved in all pa-
tients to acceptable levels and was suppressed or not 
observed in patients 4 and 15 (moderate frequency 
level) and in patients 5 and 8 (high frequency). 
AHI before treatment had a baseline mean of 18.3 
(SD=11.8). After treatment, the AHI displayed a mean 
of 4.1 (SD=3.8, p=0.001). Thus, the outcome for “after” 
is significantly less than for “before”, i.e., there was a 
highly significant reduction in AHI.
  
Figure 1 - Adjustable mandibular advancement splints used in patients with OSAHS.
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Table 1 - Anthropometric data of research participants.
Table 2 - Results of the Epworth Sleepiness Scale (ESS) before and after 
splint use.
Table 3 - Anamnesis Index (AI) results before and after splint use.
Subjects Gender
Age (years) Height
(m)
Weight (kg) BMI
Before After Before After Before After
P1 Male 35 37 1.72 83 80 28 27
P2 Male 39 42 1.69 102 103 36 36
P3 Male 40 43 1.72 78 76 26 26
P4 Female 50 52 1.48 51 52 23 24
P5 Female 59 60 1.61 70 78 27 30
P6 Female 63 64 1.8 97 97 30 30
P7 Male 28 28 1.87 114 116 33 33
P8 Female 54 55 1.57 69 69 28 28
P9 Female 40 42 1.66 63 63 23 23
P10 Female 55 55 1.57 94 94 38 38
P11 Male 63 65 1.68 92 93 33 33
P12 Male 54 56 1.69 79 76 28 27
P13 Male 57 58 1.58 66 66 26 26
P14 Male 56 57 1.67 83 83 30 30
P15 Male 47 47 1.68 75 75 27 27
Subjects Before After
P1 8 3
P2 6 2
P3 7 2
P4 11 3
P5 12 6
P6 8 7
P7 14 6
P8 13 10
P9 6 2
P10 6 2
P11 10 5
P12 6 3
P13 10 4
P14 13 3
P15 13 6
Subjects Before After
P1 8 4
P2 6 6
P3 15 0
P4 5 5
P5 15 10
P6 13 7
P7 0 0
P8 3 0
P9 0 0
P10 7 7
P11 6 0
P12 0 0
P13 15 4
P14 15 5
P15 15 5
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dISCuSSIOn
The aim of this study was to evaluate the effec-
tiveness of an adjustable intraoral mandibular ad-
vancement splint in the treatment of OSAHS.5,9,19 
Currently, it is recommended that to be consid-
ered successful OSHAS treatment using oral splints 
must comply with the following polysomnographic 
parameters: A reduction in AHI of at least 50% or a 
reduction in AHI values below ten.16
A highly significant reduction in AHI found in 15 
patients, i.e., 77.6% mean reduction, demonstrates 
that the splints can be indicated for treating snor-
ing, increased upper airway resistance syndrome 
and OSAHS cases of mild to moderate severity, al-
though some patients with severe OSAHS can also 
benefit from the therapy, such as patient 12 in this 
research. When patient 12 was excluded so that the 
data analysis could be restricted to patients with 
AHI<30 only, a highly significant improvement in 
AHI was still found, i.e., a mean 75.9% (p=0.001). 
Nine (81.8%) out of 11 patients with AHI>10 showed 
a reduction in AHI to values below ten. It was ob-
served that mandibular repositioning caused a re-
duction in AHI. Upper airway narrowing due to ana-
tomical factors such as a posterior positioning of the 
Subj. 
Lowest Saturation Desaturation Micro-awakening AHI
Before After Before After Before After Before After 
P1 91.0 92.0 1.0 0.0 11.9 1.8 11.3 0.0
P2 77.0 81.0 17.0 7.0 32.8 0.0 26.8 3.3
P3 87.2 89.0 25.0 3.0 20.0 0.0 19.3 6.0
P4 86.0 90.0 4.0 0.0 0.0 0.0 18.8 1.8
P5 87.9 92.0 1.0 0.0 0.0 6.6 8.2 0.0
P6 82.0 83.0 31.0 34.0 0.0 0.0 14.1 5.9
P7 82.0 85.0 12.0 2.0 0.0 0.0 9.7 2.6
P8 86.0 87.0 17.0 1.0 19.4 0.0 20.1 0.8
P9 88.0 94.0 0.0 0.0 9.4 0.0 0.7 1.1
P10 88.9 92.0 0.0 0.0 13.4 10.4 6.3 0.6
P11 69.0 72.0 23.0 25.0 23.7 0.0 17.7 10.2
P12 85.6 88.0 8.0 4.0 64.6 12.5 53.5 9.3
P13 77.0 83.0 47.0 32.0 0.0 0.0 22.1 6.0
P14 77.0 83.0 30.0 1.0 0.0 0.0 19.4 2.7
P15 81.0 82.0 24.0 12.0 30.7 0.0 26.4 11.8
Table 4 - Oxyhemoglobin saturation index (%) and number of arousals and obstructive events per hour (AHI).
mandible is a risk factor for sleep apnea. In advanc-
ing the mandible, the splints widen and stretch the 
muscles, which concurrently produce an increase 
in electromyographic activity, widening the airway 
and improving airflow.1,2,14,17,19,26 
Thirteen patients (86.7%) exhibited some de-
gree of tooth sensitivity, especially on awakening in 
the morning.  With splint use, five patients (33%) 
complained of excessive salivation at night and one 
patient (6.6%) complained of dry mouth at night. In 
this study, specifically in regard to the development 
of joint or muscle pain, therapy with splints did not 
produce definitive or reversible TMD signs or symp-
toms. Yoshida29 found these effects in 8.5% of cases 
and described them as transient. None of the partic-
ipants was diagnosed with TMD prior to treatment, 
and after treatment completion (12-month follow-
up, on average), no signs or symptoms of TMD-re-
lated muscle or joint dysfunction were identified. 
It is noteworthy that harmful side effects such 
as tooth sensitivity (86.7%), dry mouth or exces-
sive salivation (40%) occurred after splint place-
ment but on examination were considered minor 
or mild.12,19,23,24,25 
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Authors have indicated that the advancement 
should be between 50% and 75% of maximum man-
dibular protrusion2 since such repositioning would 
be within the measurements of a physiological man-
dibular protrusion.22 Six patients had muscle pain 
and two patients (P6 and P15) presented with mod-
erate pain, which prevented further advancement 
to 75% maximum protrusion, although the pain was 
controlled with non-steroidal anti-inflammatory 
medication. No other changes occurred in AI, indi-
cating no development of TMD signs and symptoms.
The splints were inserted at 60% maximum pro-
trusion and advanced in increments of 0.5 mm to 1 
mm within two weeks, unlike other studies, which 
made weekly advancements of 0.25 mm.20
In this study, the mean mandibular advance-
ment was 9.17 mm, ranging from 7 to 12 mm, there-
fore within what is considered a physiological pro-
trusion length. These results are similar to several 
studies that proved the effectiveness of splints in 
mild and moderate OSAHS.5,9,30
Advancement was discontinued based on the follow-
ing criteria: A position that coincided with 75% maxi-
mum protrusion and improvement in subjective criteria 
reported by patients. Clinically, however, defining such 
criteria can prove elusive. Some authors have therefore 
suggested an association with objective parameters at 
the end of mandibular advancement therapy, such as 
nocturnal pulse oximetry performed at home.10,28
Reports of improvement in snoring and daytime 
sleepiness led four patients (26.7%) to an early referral 
for a second PSG, but the results showed no change in 
AHI. This situation showed that the reports of patients 
and/or of their room-mates are indeed subjective and 
not a substitute for polysomnography as a therapeutic 
assessment tool.9,16 Further advancements were made 
in these patients and another PSG was performed for 
each one, except for patient P11, who refused to repeat 
it and was the only patient who showed no reduction 
in AHI above 50% (42.4% reduction).
Therapy with the splint caused a direct effect on 
sleep fragmentation as there was an increase in the 
lowest oxyhemoglobin saturation index (p=0.05) and 
a significant decrease in total desaturation and num-
ber of arousals (p=0.05). Clinically, improvement in 
polysomnographic parameters was found to be relat-
ed to a significant decrease (p=0.05) in ESS.8,19 
Improvement in snoring levels was observed in 
all cases and the subjective assessment of spouse 
confirmed this result. Spouse satisfaction is ex-
tremely important since for him or her snoring can 
cause another sleep disorder, i.e., insomnia.4
Long-term studies are warranted to compare 
the designs and materials used in the splints and 
to verify the occurrence of any potential desirable 
or undesirable effects.3 However, even if signifi-
cant side effects do occur, a thorough evaluation 
- pinpointing favorable and unfavorable biological 
factors - should be conducted and discussed to en-
able treatment decisions that benefit the patient 
in the best possible way while gaining control over 
the important and severe complications of OSAHS. 
Although treatment using a splint is regarded as a 
non-invasive therapy, side effects are likely to oc-
cur during treatment. Occlusal changes may occur 
with long-term use, so patients should be strictly 
controlled.27
When patients feel the benefits of therapy us-
ing the splint and realize that they are waking up 
feeling rested, they start wearing it on a daily and 
continuous basis.13
Although this splint was fabricated with materi-
als normally used in dental practice (such as acrylic 
resin), in light of the limitations of this study and 
the success criteria adopted for the AHI reduction 
(above 50%), splint effectiveness was successfully 
evaluated and the results consistent with those 
found in the literature.
  
COnCluSIOnS
Results indicated that the splint developed for 
this study proved to be a viable alternative for 
treatment of mild to moderate OSAHS. Therapy 
using splints did not developed definitive TMD 
signs and symptoms during the evaluation period. 
There was a highly significant reduction in AHI 
above 50% in 93.3% of patients (mean 77.6%) an 
increase in lower oxygen saturation, reduction in 
desaturation, decreased number of micro-awak-
enings or EEG arousals, and subjective improve-
ment in snoring and excessive daytime sleepiness. 
Undesirable effects were considered minimal and 
controllable, and no definitive TMD signs and 
symptoms were found to occur.
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